FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018889239> ?p ?o ?g. }

• W2018889239 endingPage "224" @default.
• W2018889239 startingPage "219" @default.
• W2018889239 abstract "Many patients with metastatic breast cancer (MBC) have been treated previously with taxanes and/or anthracyclines, which renders reinduction of anthracyclines in the palliative setting impossible because of the high cardiotoxicity of these drugs. Pegylated liposomal doxorubicin represents a means of reinducing anthracyclines without increasing cardiotoxicity. The aim of this retrospective study was to evaluate the efficacy and toxicity of Caelyx in patients with MBC. Patients with histologically confirmed MBC were eligible for this retrospective study if they had received palliative chemotherapy with pegylated liposomal doxorubicin between 1 January 2002 and 31 December 2006 at the Department for Gynecology and Obstetrics at the University of Heidelberg (Germany). The main endpoints were time to progression, overall survival, and safety of the treatment with pegylated liposomal doxorubicin. In all, 141 patients were included in this retrospective trial. The median age of the patients was 54 years (range 24–84 years). Of the patients, 43% had received five to six previous chemotherapy regimens before pegylated liposomal doxorubicin was recommended. In 33% of patients, more than three organs were involved. The most commonly involved organs were bones, liver, and lungs; 37 patients had received three or at least six cycles of Caelyx. During the treatment with pegylated liposomal doxorubicin, left ventricular ejection function was not reduced by more than 15%. The major effects (grade 4) were hematological toxicity (anemia, leukopenia, and thrombocytopenia), hand–foot syndrome, and stomatitis. In nine patients, the dose was reduced and in three patients chemotherapy with Caelyx was stopped owing to hematological toxicity. In 20 patients, the dose was reduced and in nine patients chemotherapy was stopped owing to nonhematological toxicity. The median time to disease progression was 6.5 months; the overall median survival was 13 months after the first course of pegylated liposomal doxorubicin was initiated. This retrospective study confirmed the efficacy and good tolerability of pegylated liposomal doxorubicin in patients with MBC who had been treated previously with anthracycline. A dosage of 40 mg/m2 body surface every 4 weeks is equally effective with less toxicity." @default.
• W2018889239 created "2016-06-24" @default.
• W2018889239 creator A5004684398 @default.
• W2018889239 creator A5004686505 @default.
• W2018889239 creator A5011232197 @default.
• W2018889239 creator A5024419542 @default.
• W2018889239 creator A5028882183 @default.
• W2018889239 creator A5037624587 @default.
• W2018889239 creator A5054599022 @default.
• W2018889239 creator A5056443691 @default.
• W2018889239 creator A5067246293 @default.
• W2018889239 creator A5069383705 @default.
• W2018889239 creator A5075058868 @default.
• W2018889239 creator A5084545133 @default.
• W2018889239 creator A5085380597 @default.
• W2018889239 creator A5089392438 @default.
• W2018889239 date "2014-02-01" @default.
• W2018889239 modified "2023-10-04" @default.
• W2018889239 title "Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer" @default.
• W2018889239 cites W1492360552 @default.
• W2018889239 cites W1987593270 @default.
• W2018889239 cites W2015815662 @default.
• W2018889239 cites W2027544639 @default.
• W2018889239 cites W2029458457 @default.
• W2018889239 cites W2038627527 @default.
• W2018889239 cites W2041934614 @default.
• W2018889239 cites W2053681261 @default.
• W2018889239 cites W2101742864 @default.
• W2018889239 cites W2135274807 @default.
• W2018889239 cites W2157470118 @default.
• W2018889239 doi "https://doi.org/10.1097/cad.0000000000000037" @default.
• W2018889239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24247203" @default.
• W2018889239 hasPublicationYear "2014" @default.
• W2018889239 type Work @default.
• W2018889239 sameAs 2018889239 @default.
• W2018889239 citedByCount "24" @default.
• W2018889239 countsByYear W20188892392014 @default.
• W2018889239 countsByYear W20188892392015 @default.
• W2018889239 countsByYear W20188892392016 @default.
• W2018889239 countsByYear W20188892392017 @default.
• W2018889239 countsByYear W20188892392018 @default.
• W2018889239 countsByYear W20188892392019 @default.
• W2018889239 countsByYear W20188892392020 @default.
• W2018889239 countsByYear W20188892392022 @default.
• W2018889239 countsByYear W20188892392023 @default.
• W2018889239 crossrefType "journal-article" @default.
• W2018889239 hasAuthorship W2018889239A5004684398 @default.
• W2018889239 hasAuthorship W2018889239A5004686505 @default.
• W2018889239 hasAuthorship W2018889239A5011232197 @default.
• W2018889239 hasAuthorship W2018889239A5024419542 @default.
• W2018889239 hasAuthorship W2018889239A5028882183 @default.
• W2018889239 hasAuthorship W2018889239A5037624587 @default.
• W2018889239 hasAuthorship W2018889239A5054599022 @default.
• W2018889239 hasAuthorship W2018889239A5056443691 @default.
• W2018889239 hasAuthorship W2018889239A5067246293 @default.
• W2018889239 hasAuthorship W2018889239A5069383705 @default.
• W2018889239 hasAuthorship W2018889239A5075058868 @default.
• W2018889239 hasAuthorship W2018889239A5084545133 @default.
• W2018889239 hasAuthorship W2018889239A5085380597 @default.
• W2018889239 hasAuthorship W2018889239A5089392438 @default.
• W2018889239 hasConcept C121608353 @default.
• W2018889239 hasConcept C126322002 @default.
• W2018889239 hasConcept C143998085 @default.
• W2018889239 hasConcept C2775930923 @default.
• W2018889239 hasConcept C2776694085 @default.
• W2018889239 hasConcept C2778233292 @default.
• W2018889239 hasConcept C2779194965 @default.
• W2018889239 hasConcept C2781303535 @default.
• W2018889239 hasConcept C29730261 @default.
• W2018889239 hasConcept C530470458 @default.
• W2018889239 hasConcept C71924100 @default.
• W2018889239 hasConcept C90924648 @default.
• W2018889239 hasConcept C98274493 @default.
• W2018889239 hasConceptScore W2018889239C121608353 @default.
• W2018889239 hasConceptScore W2018889239C126322002 @default.
• W2018889239 hasConceptScore W2018889239C143998085 @default.
• W2018889239 hasConceptScore W2018889239C2775930923 @default.
• W2018889239 hasConceptScore W2018889239C2776694085 @default.
• W2018889239 hasConceptScore W2018889239C2778233292 @default.
• W2018889239 hasConceptScore W2018889239C2779194965 @default.
• W2018889239 hasConceptScore W2018889239C2781303535 @default.
• W2018889239 hasConceptScore W2018889239C29730261 @default.
• W2018889239 hasConceptScore W2018889239C530470458 @default.
• W2018889239 hasConceptScore W2018889239C71924100 @default.
• W2018889239 hasConceptScore W2018889239C90924648 @default.
• W2018889239 hasConceptScore W2018889239C98274493 @default.
• W2018889239 hasIssue "2" @default.
• W2018889239 hasLocation W20188892391 @default.
• W2018889239 hasLocation W20188892392 @default.
• W2018889239 hasOpenAccess W2018889239 @default.
• W2018889239 hasPrimaryLocation W20188892391 @default.
• W2018889239 hasRelatedWork W2018180569 @default.
• W2018889239 hasRelatedWork W2051526468 @default.
• W2018889239 hasRelatedWork W2094475704 @default.
• W2018889239 hasRelatedWork W2114627331 @default.
• W2018889239 hasRelatedWork W2118967594 @default.
• W2018889239 hasRelatedWork W2143449387 @default.
• W2018889239 hasRelatedWork W2305100815 @default.

• next